William Blair Analysts Decrease Earnings Estimates for Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) – Equities research analysts at William Blair lowered their FY2024 earnings estimates for Sarepta Therapeutics in a research report issued to clients and investors on Wednesday, April 17th. William Blair analyst T. Lugo now expects that the biotechnology company will earn $6.66 per share for the year, down from their prior forecast of $6.74. The consensus estimate for Sarepta Therapeutics’ current full-year earnings is $2.14 per share. William Blair also issued estimates for Sarepta Therapeutics’ FY2025 earnings at $14.91 EPS.

A number of other research analysts have also commented on SRPT. Barclays upped their price objective on shares of Sarepta Therapeutics from $141.00 to $185.00 and gave the company an “overweight” rating in a research report on Thursday, February 29th. BMO Capital Markets began coverage on shares of Sarepta Therapeutics in a research report on Wednesday, January 31st. They set an “outperform” rating and a $170.00 price objective for the company. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $128.00 price objective on shares of Sarepta Therapeutics in a research report on Thursday, February 29th. Mizuho upped their price objective on shares of Sarepta Therapeutics from $130.00 to $145.00 and gave the company a “buy” rating in a research report on Wednesday, February 14th. Finally, Citigroup increased their price target on shares of Sarepta Therapeutics from $160.00 to $172.00 and gave the stock a “buy” rating in a research report on Thursday, February 29th. Four analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $158.38.

Sarepta Therapeutics Stock Down 0.8 %

Shares of SRPT opened at $115.62 on Friday. The company has a 50-day simple moving average of $126.52 and a 200-day simple moving average of $110.41. The firm has a market capitalization of $10.86 billion, a P/E ratio of -18.89 and a beta of 0.94. The company has a debt-to-equity ratio of 1.32, a quick ratio of 3.45 and a current ratio of 3.95. Sarepta Therapeutics has a 52 week low of $55.25 and a 52 week high of $159.89.

Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings results on Wednesday, February 28th. The biotechnology company reported $0.47 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.50. Sarepta Therapeutics had a negative net margin of 43.11% and a negative return on equity of 18.97%. The company had revenue of $396.80 million during the quarter, compared to analysts’ expectations of $387.18 million. During the same period in the prior year, the company earned ($1.24) earnings per share. The business’s quarterly revenue was up 53.6% compared to the same quarter last year.

Institutional Trading of Sarepta Therapeutics

Several hedge funds have recently modified their holdings of the stock. Hudson Capital Management LLC bought a new stake in shares of Sarepta Therapeutics during the first quarter valued at approximately $220,000. Wealth Enhancement Advisory Services LLC grew its stake in shares of Sarepta Therapeutics by 100.5% during the first quarter. Wealth Enhancement Advisory Services LLC now owns 4,996 shares of the biotechnology company’s stock valued at $647,000 after purchasing an additional 2,504 shares during the last quarter. Mather Group LLC. bought a new stake in shares of Sarepta Therapeutics during the first quarter valued at approximately $28,000. GAMMA Investing LLC grew its stake in shares of Sarepta Therapeutics by 37.0% during the first quarter. GAMMA Investing LLC now owns 322 shares of the biotechnology company’s stock valued at $42,000 after purchasing an additional 87 shares during the last quarter. Finally, Vanguard Group Inc. grew its stake in shares of Sarepta Therapeutics by 2.8% during the fourth quarter. Vanguard Group Inc. now owns 8,816,124 shares of the biotechnology company’s stock valued at $850,139,000 after purchasing an additional 243,180 shares during the last quarter. 86.68% of the stock is owned by institutional investors.

Insider Transactions at Sarepta Therapeutics

In other news, Director Hans Lennart Rudolf Wigzell sold 15,000 shares of the firm’s stock in a transaction that occurred on Friday, March 8th. The shares were sold at an average price of $123.25, for a total transaction of $1,848,750.00. Following the completion of the sale, the director now owns 22,840 shares of the company’s stock, valued at $2,815,030. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. In other news, Director Kathryn Jean Boor sold 761 shares of the stock in a transaction that occurred on Monday, March 11th. The shares were sold at an average price of $122.93, for a total transaction of $93,549.73. Following the sale, the director now directly owns 7,516 shares of the company’s stock, valued at $923,941.88. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Hans Lennart Rudolf Wigzell sold 15,000 shares of the stock in a transaction that occurred on Friday, March 8th. The shares were sold at an average price of $123.25, for a total transaction of $1,848,750.00. Following the sale, the director now directly owns 22,840 shares in the company, valued at $2,815,030. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 22,096 shares of company stock valued at $2,739,419. Corporate insiders own 7.40% of the company’s stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.